RxDoctor Payments Data

Nicholas Ditullio, MD

Internal Medicine · Pittsburgh, PANPI 1275597619

Payments from drug & device makers

$1,020in general payments, 2019–2025

Across 45 payments — averaging $22.67 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Sunovion Pharmaceuticals Inc.$182
  • Edwards Lifesciences$153
  • Veryan Medical Incorporated$146
  • Pfizer$77
  • Novartis$76
  • Johnson & Johnson$73
  • plus $314 from 8 others

What the payments were for

  • Food & beverage$1,020100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
23
24

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,020 in reported general payments places this provider in the 75th percentile of 5,705 internal medicine providers in Pennsylvania.

See all internal medicine providers in Pennsylvania

Medicare billing

Part B allowed, 2024
$142,131
Medicare patients
477
Services billed
1,375

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban714$267,042
XareltoRivaroxaban151$46,079
JardianceEmpagliflozin99$44,799
JanuviaSitagliptin Phosphate107$44,725
FarxigaDapagliflozin Propanediol65$39,991
Trelegy ElliptaFluticasone/Umeclidin/Vilanter43$33,899
EntrestoSacubitril/Valsartan76$30,641
TradjentaLinagliptin76$28,876
RybelsusSemaglutide12$22,905
OzempicSemaglutide19$17,295
Atorvastatin Calcium946$14,333
Aripiprazole93$13,656
MyrbetriqMirabegron30$13,521
TrulicityDulaglutide11$11,538
Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog47$10,385

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$77$267,042714 claims
Johnson & JohnsonXarelto$73$46,079151 claims
GSKTrelegy Ellipta, Breo Ellipta, Incruse Ellipta$72$44,89470 claims
NovartisEntresto$76$30,64176 claims
AbbVieLinzess$36$9,90718 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 5,705 internal medicine providers in Pennsylvania.

Other internal medicine in Pittsburgh

See the full list for Pennsylvania

Where these figures come from

Is this you, or does something look wrong? →